@article {Luft1109, author = {Luft, Vivian C. and Schmidt, Maria In{\^e}s and Pankow, James S. and Hoogeveen, Ron C. and Couper, David and Heiss, Gerardo and Duncan, Bruce B. and ,}, title = {Dipeptidyl Peptidase IV and Incident Diabetes}, volume = {33}, number = {5}, pages = {1109--1111}, year = {2010}, doi = {10.2337/dc09-1996}, publisher = {American Diabetes Association}, abstract = {OBJECTIVE Dipeptidyl peptidase IV (DPP-IV) is not only important in β-cell function but also has proinflammatory actions. We aimed to investigate whether it could act as a link between low-grade chronic inflammation and diabetes. RESEARCH DESIGN AND METHODS Using a case-cohort design, we followed 546 middle-aged individuals who developed diabetes and 538 who did not over \~{}9 years within the Atherosclerosis Risk in Communities study. RESULTS In weighted analyses, the correlation between DPP-IV levels and anthropometric, inflammatory, or metabolic variables was minimal (Spearman correlations \<0.11). Those who developed diabetes had mean DPP-IV values similar to those who did not (P = 0.18). Individuals in the highest quartile of DPP-IV were not at greater risk of diabetes (hazard ratio 0.88 [95\% CI 0.62{\textendash}1.24]) in Cox proportional hazards models adjusting for age, sex, race, study center, and multiple additional diabetes risk factors. CONCLUSIONS Fasting DPP-IV levels do not appear to predict incident diabetes. {\textcopyright} 2010 by the American Diabetes Association.}, issn = {0149-5992}, URL = {https://care.diabetesjournals.org/content/33/5/1109}, eprint = {https://care.diabetesjournals.org/content/33/5/1109.full.pdf}, journal = {Diabetes Care} }